CR Group L.P. - 12 Apr 2024 Form 4 Insider Report for T2 Biosystems, Inc. (TTOO)

Footnote F1

Pursuant to that certain Securities Purchase Agreement, dated February 15, 2024, by and among the Company, CRG Partners III L.P., CRG Partners III - Parallel Fund (A) L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P. and CRG Partners III - Parallel Fund B (Cayman) L.P. (collectively, the "CRG Entities"), the CRG Entities received these shares of common stock in exchange for the CRG Entities surrendering for cancellation of certain outstanding debt.

Footnote F2

CR Group L.P. may be deemed to beneficially own these shares by virtue of its position as the investment manager for the CRG Entities.

Footnote F3

Each share of Series A Convertible Preferred Stock (the "Series A Preferred") converts into 100 shares of the Company's common stock at the holder's election, subject to beneficial ownership limitations, including that a holder of Series A Preferred is prohibited from converting such shares into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 49.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. As a result of the 49.99% beneficial ownership limitation, as of April 12, 2024, the Series A Preferred held by the reporting persons can be converted into a maximum of 1,173,600 shares of common stock in the aggregate. The shares of Series A Preferred have no expiration date.

Footnote F4

The preferred stock has no expiration date.